Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of …
During a call with analysts last month, Regeneron said it didn’t expect to record additional sales of its COVID-19 antibodies to the United States this …
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and …
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients with …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
